Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday.

The deal gives Otsuka a pipeline based

Read the full 309 word article

User Sign In